Cortexyme (NASDAQ: CRTX) is a clinical stage bio-pharmaceutical company working on Alzheimer's and other degenerative diseases. The company currently has one molecule in its pipeline, called COR388, that has advanced through pre-clinical and Phase 1b testing and is currently the subject of a...